Phathom Pharmaceuticals

Phathom Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment landscape for acid-related gastrointestinal (GI) disorders. They focus on developing and commercializing innovative therapeutics, particularly potassium-competitive acid blockers (PCABs). The company has completed Phase 3 clinical trials for treatments of Erosive GERD, Non-Erosive GERD, and H. pylori infection, and plans to soon initiate an additional Phase 3 trial investigating a novel “As Needed” dosing regimen for patients with Non-Erosive GERD.

Phathom is committed to building a diverse and inclusive workplace, and they refer to their employees as "Phamily." They offer competitive benefits and perks, including a comprehensive health coverage plan, unlimited time off, paid holidays, and a winter break shutdown. Phathom also has a strong commitment to supporting researchers, healthcare providers, patients, and their advocates through grants and sponsorships focused on the development of innovative treatments for acid-related GI disorders.

Phathom Pharmaceuticals offers a flexible work environment, allowing employees to balance their work and personal lives. They offer hybrid and flex working arrangements, unlimited time off, and paid holidays, as well as a winter break shutdown. This demonstrates a commitment to employee well-being and supports a healthy work-life balance.

Phathom Pharmaceuticals provides a comprehensive benefits package to its employees, including competitive health coverage options with low monthly premiums, a company-funded HSA plan, short- and long-term disability, unlimited time off, paid holidays, and a winter break shutdown. They also offer hybrid and flex working arrangements, professional development opportunities, an employee recognition program, annual fitness and wellness reimbursement, company swag and snacks, regular office happy hours, employee discounts, and pet insurance.

Phathom Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of acid-related gastrointestinal disorders. They are focused on developing and commercializing new treatments for gastrointestinal diseases, with a particular emphasis on potassium-competitive acid blockers (PCABs), a novel class of drugs. They aim to disrupt the status quo in acid-related GI treatment and bring much-needed innovation to the market, ultimately improving the lives of patients suffering from these conditions.

Phathom Pharmaceuticals promotes a collaborative and supportive culture, emphasizing teamwork and a shared passion for improving the lives of patients. The company encourages a nimble, entrepreneurial environment that fosters collective ownership, accountability, and innovation. They celebrate personal and professional milestones, support each other through challenges, and foster an inclusive environment that values respect, learning, and growth.

Phathom Pharmaceuticals is committed to fostering a diverse, equitable, and inclusive workplace. They believe that a diverse workforce strengthens their ability to develop innovative treatments for gastrointestinal diseases. Phathom actively promotes equal opportunity for all applicants and employees, regardless of race, color, religion, sex, sexual orientation, gender identity, national origin, disability, veteran status, or other legally protected characteristics. They strive to create a welcoming and supportive environment where everyone feels valued, respected, and empowered to contribute their unique perspectives.